Home › Prescription medicine › Cipla USA, Inc. — Diclofenac Sodium Topical…
Cipla USA, Inc. — Diclofenac Sodium Topical Gel, 1%, NET WT 100 g (3.53 oz)
Do not stop taking this without speaking to your pharmacist or doctor.
What’s wrong
Failed PH Specifications
The Recall Registry rates this labelling issue — FDA Class III: unlikely to cause harm.
What to do
Check the lot numbers below against what you have. Do not stop taking a prescription medicine because of a recall without speaking to your pharmacist or doctor first — for many medicines stopping is more harmful than continuing, and they can tell you whether yours is affected and what to do about it.
Who to contact: Recalling firm: Cipla USA, Inc.
The product
Diclofenac Sodium Topical Gel, 1%, NET WT 100 g (3.53 oz), Manufactured by: DPT Laboratories, Ltd., 307 E Josephine Street, San Antonio, TX 78215. NDC: 76282-103-39
Details
- Units affected
- 92,376 tubes
- Recall date
- December 22, 2025
- Brand
- Cipla USA, Inc.
Nationwide in the USA
The official notice
This recall was issued by the U.S. Food and Drug Administration. The Recall Registry summarises it — always confirm the details at the source.
Their exact wording: “Cipla USA, Inc. — Diclofenac Sodium Topical Gel, 1%, NET WT 100 g (3.53 oz), Manufactured by: DPT Laboratories, Ltd., 307 E Josephine Street, San Antonio, TX 78215. NDC: 76282-103-39”
Worried about the other things in your house? You can write down what you have and be told if one is recalled — or, if you sell second-hand, check your whole stock at once.
Filed under: Prescription medicine